Cannabis Training Courses
Clinical Cannabinoid Medicine Curriculum (SCC 2018)
Developed by the Society of Cannabis Clinicians (SCC), this is the first comprehensive, online CME-certified curriculum in Clinical Cannabinoid Medicine designed to educate the practicing clinician on both the research and clinical practice aspects of the therapeutic use of cannabis — 5.5 CME Credits, 13 AAFP Elective Credits.
Medical Cannabis Curriculum for Nurses
ACNA and TMCI have collaborated to develop the first comprehensive, online medical cannabis curriculum for nurses. Topics include the Endocannabinoid System, Dosing, Medical Risks and Legal Implications
2018 New York State Healthcare Provider Education: Medical Use of Marijuana
Developed in cooperation between the New York State Department of Health (NYSDOH) and the Society of Cannabis Clinicians (SCC), this online curriculum is designed to educate Practitioners who wish to register with the Department to certify patients for the medical use of marijuana under New York State’s Compassionate Care Act and pharmacists who will be working in dispensing facilities of registered organizations
Core Knowledge of the Endocannabinoid System 2018
Dr. Dustin Sulak presents the endocannabinoid system, cannabinoid receptors and the effect of endocannabinoids on physiologic systems.
Role of the Clinician: Helping Patients Optimize Their Therapeutic Relationship with Cannabis
Have you wondered how to discuss medical cannabis with patients and how to manage dosing and side effects? This online course by Dr. Sulak describes the critical education topics professionals should broach with patients, basic dosing strategies and how to anticipate any side effects. The learner will get a unique perspective on Dr. Sulak’s Sensitization Protocol and insight into the cognitive and neuroplastic changes that lead to symptom relief and healing.
Washington State Healthcare Provider Education: Medical Use of Marijuana
Developed by TMCI Global and approved by the Washington State Department of Health (WADOH), this online curriculum is designed to educate practitioners who wish to participate in the Washington State Department of Health Medical Marijuana Program.
Clinical Applications of Cannabis in Cancer Patients
Understanding the challenges with symptom management associated with cancer, Dr. Abrams examines cannabis in relation to pain management, appetite, and chemotherapy. The course includes a specific look at the interaction between cannabis and opioids in a trial, as well as the potential for cannabis as an anti-cancer agent.
Cannabinoids and Neuropathic Pain
How can and should cannabinoids be added to the analgesic formulary? Dr. Fine reviews the management of pain and types of pain and then explores the impact of cannabis on neuropathic pain through a review of clinical trials. A close look at the myriad of receptors in the brain involved in the perception or experience of pain reveals the potential for medical cannabis in this complex system.
Cannabis Therapeutics in Hospice and Palliative Care
Dr. Sunil Aggarwal takes the learner through a survey of Cannabis in relation to Modern Palliative Care, with an emphasis on its use for symptom control. How does Cannabis compare to opioids in pain management and morbidity? Using research and case studies, Dr. Aggarwal explores the data on quality of life and takes a look at the understanding of Cannabis use within the hospice healthcare profession.
Cannabinoids: Tackling the Cardiovascular Problems
Cardiovascular diseases (CVD) are the leading cause of death and disability in the world, with a major impact on longevity and healthcare costs in the U.S. Dr. Smoum-Jaouni examines the endocannabinoid system, CB 1 and CB 2 expression in the CV system, and the impact of cannabis on the regulation of vessel contractility. Specific diseases will be discussed including diabetes, atherosclerosis and restenosis, and ischemia/reperfusion injury.
Cannabis in the Management of Neuromuscular Disorders
Dr. Carter explores cannabis use for neuropathic pain, including discussion of the administration of various cannabis formulations. Learners will have a closer look at clinical pharmacology of cannabis along with an examination of cannabinoid receptors and key endocannabinoid system elements. Through a review of key literature and research, Dr. Carter presents the potential of cannabis as a powerful therapeutic option in the management of neuromuscular disorders.
Endocannabinoids in the Circulation and Psychopathology
This course by Dr. Hillard examines the basic science and human research studies looking at patients with psychopathologies and the impact of dysregulated endocannabinoid signaling. What role does endocannabinoid signaling play in stress dampening and recovery, and what is Endocannabinoid Deficiency Syndrome? These and other topics will be explored through a look at specific psychopathologies such as anxiety, depression and PTSD.
New Target Receptors for Cannabinoids: GPR55 and GPR18
What is the evidence for additional cannabinoid receptors and what might they do? Dr. Abood takes learners through a close look at the endogenous cannabinoid system and the endogenous ligands that have been identified. Through a review of the receptor molecular structure and agonist/antagonist screens, the learner will see the potential for these receptors playing a physiological role in the central nervous system.
Potential Therapeutic Benefits of Cannabidiol for Cancer Patients
Dr. Ward discusses the interaction between cancer and cannabinoids, drawing distinctions between phytocannabinoids, endocannabinoids, and synthetic cannabinoids. She presents a detailed description of the phytocannabinoid Cannabidiol, outlining its therapeutic potential for the treatment of the primary and secondary health consequences of cancer.
Is Your Patient Impaired by Cannabis?
What exactly are the potential impairments brought on by the use of medical cannabis? Paul Armentano leads learners through research on cannabis-influenced changes on psychomotor performance and cognitive abilities, as well as looks at the traditional measures for drug detection methods and how and if this relates to impairment.